Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from China NT Pharma Group Co., Ltd. ( (HK:1011) ).
China NT Pharma Group Company Limited has requested a trading halt in its shares on the Hong Kong Stock Exchange, effective from the morning of 10 February 2026. The suspension comes as the company prepares to issue supplemental information related to its previously announced plan to issue convertible bonds under a general mandate.
The halt indicates that key details on the convertible bond issuance are still pending, and trading will remain paused until the market receives further clarification. Investors and stakeholders are likely to watch closely for the additional disclosures, as the terms of the convertible bonds could affect the company’s capital structure and near-term financing strategy.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.76 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Company Limited is a pharmaceutical company listed on the Hong Kong Stock Exchange, focusing on the development and commercialization of healthcare and drug products for the Chinese and regional markets. The company operates under a board comprising executive, non-executive, and independent non-executive directors, reflecting a typical Hong Kong-listed corporate governance structure.
Average Trading Volume: 299,298
Technical Sentiment Signal: Hold
Current Market Cap: HK$532.7M
Find detailed analytics on 1011 stock on TipRanks’ Stock Analysis page.